{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:48:15Z","timestamp":1792097295426,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Patient Education and Counseling"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.pec.2026.110342","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:18:10Z","timestamp":1791645490000},"page":"110342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploring patient and clinician perspectives for homologous recombination deficient (HRD) biomarker testing to guide precision medicine for advanced ovarian cancer treatment: A qualitative study"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3774-6442","authenticated-orcid":false,"given":"Julia","family":"McKenna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Payandeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena","family":"Aizenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melica Nourmoussavi","family":"Brodeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0473-6993","authenticated-orcid":false,"given":"Mark","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8636-6342","authenticated-orcid":false,"given":"Iwa","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice S.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Pepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Willows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5451-0845","authenticated-orcid":false,"given":"Helen","family":"McTaggart-Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pec.2026.110342_bib1","unstructured":"Ovarian cancer statistics | Canadian Cancer Society [Internet]. [cited 2025 Nov 27]. Available from: https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/ovarian\/statistics."},{"key":"10.1016\/j.pec.2026.110342_bib2","unstructured":"Recurrence | Ovarian Cancer Research Alliance [Internet]. [cited 2025 Nov 27]. Available from: https:\/\/ocrahope.org\/for-patients\/recurrence\/."},{"issue":"4","key":"10.1016\/j.pec.2026.110342_bib3","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/ijms20040952","article-title":"High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints","volume":"20","author":"Lisio","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pec.2026.110342_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"10.1016\/j.pec.2026.110342_bib5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","article-title":"Homologous recombination deficiency: concepts, definitions, and assays","volume":"27","author":"Stewart","year":"2022","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.pec.2026.110342_bib6","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.3390\/cancers15123095","article-title":"Prevalence of homologous recombination deficiency in first-line PARP inhibitor maintenance clinical trials and further implication of personalized treatment in ovarian cancer","volume":"15","author":"Paik","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.pec.2026.110342_bib7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.gore.2019.07.007","article-title":"BRCA mutation in high grade epithelial ovarian cancers","volume":"29","author":"Manchana","year":"2019","journal-title":"Gynecol Oncol Rep"},{"issue":"26","key":"10.1016\/j.pec.2026.110342_bib8","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pec.2026.110342_bib9","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ygyno.2018.01.011","article-title":"The poly (ADP ribose) polymerase inhibitor niraparib: management of toxicities","volume":"149","author":"Moore","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pec.2026.110342_bib10","unstructured":"Precision care and comprehensive research strategy for ovarian cancer patients: Beyond PARP inhibitors [Internet]. [cited 2024 Jul 25]. Available from: https:\/\/www.marathonofhopecancercentres.ca\/our-research\/project\/precision-care-and-comprehensive-research-strategy-for-ovarian-cancer-patients-beyond-parp-inhibitors."},{"issue":"4","key":"10.1016\/j.pec.2026.110342_bib11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/bmjebm-2022-112068","article-title":"Shared decision-making as a method of care","volume":"28","author":"Montori","year":"2023","journal-title":"BMJ Evid-Based Med"},{"issue":"5","key":"10.1016\/j.pec.2026.110342_bib12","first-page":"1","article-title":"Recombination deficiency testing to inform patient decisions about Niraparib maintenance therapy for high-grade serous or endometrioid epithelial ovarian cancer: a health technology assessment","volume":"23","author":"Homologous","year":"2023","journal-title":"Ont Health Technol Assess Ser"},{"key":"10.1016\/j.pec.2026.110342_bib13","unstructured":"Guan Q., Aktar S., Pataky R., Stephen M.M., Marques M., Forster K., et al. The Safety of Niraparib in Ovarian Cancer."},{"key":"10.1016\/j.pec.2026.110342_bib14","unstructured":"The Society of Gynecologic Oncology of Canada [Internet]. [cited 2026 Feb 18]. Home. Available from: https:\/\/gyneoncology.ca\/."},{"key":"10.1016\/j.pec.2026.110342_bib15","article-title":"Applying the health belief model to explore healthcare provider and patient perspectives on homologous recombination deficiency testing in cancer: a narrative review","volume":"47","author":"Kim","year":"2026","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.pec.2026.110342_bib16","unstructured":"Ovarian Cancer Canada [Internet]. [cited 2026 Feb 10]. Ovarian Cancer Experience, Research. Available from: https:\/\/ovariancanada.org\/."},{"key":"10.1016\/j.pec.2026.110342_bib17","doi-asserted-by":"crossref","unstructured":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups | International Journal for Quality in Health Care | Oxford Academic [Internet]. [cited 2026 Aug 20]. Available from: https:\/\/academic.oup.com\/intqhc\/article\/19\/6\/349\/1791966.","DOI":"10.1093\/intqhc\/mzm042"},{"key":"10.1016\/j.pec.2026.110342_bib18","doi-asserted-by":"crossref","unstructured":"Supporting best practice in reflexive thematic analysis reporting in Palliative Medicine: A review of published research and introduction to the Reflexive Thematic Analysis Reporting Guidelines (RTARG) [Internet]. [cited 2026 Aug 20]. Available from: https:\/\/journals.sagepub.com\/doi\/epdf\/10.1177\/02692163241234800?src=getftr&utm_source=sciencedirect_contenthosting&getft_integrator=sciencedirect_contenthosting doi:10.1177\/02692163241234800.","DOI":"10.1177\/02692163241234800"},{"key":"10.1016\/j.pec.2026.110342_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.metip.2024.100155","article-title":"How do you solve a problem like COREQ? A critique of Tong et al.\u2019s (2007) consolidated criteria for reporting qualitative research","volume":"11","author":"Braun","year":"2024","journal-title":"Methods Psychol"},{"issue":"2","key":"10.1016\/j.pec.2026.110342_bib20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"9280","key":"10.1016\/j.pec.2026.110342_bib21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0140-6736(01)05627-6","article-title":"Qualitative research: standards, challenges, and guidelines","volume":"358","author":"Malterud","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pec.2026.110342_bib22","unstructured":"NVivo: Leading Qualitative Data Analysis Software | Lumivero [Internet]. [cited 2025 Nov 27]. Available from: https:\/\/lumivero.com\/products\/nvivo\/."},{"issue":"4","key":"10.1016\/j.pec.2026.110342_bib23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/2159676X.2019.1628806","article-title":"Reflecting on reflexive thematic analysis","volume":"11","author":"Braun","year":"2019","journal-title":"Qual Res Sport Exerc Health"},{"issue":"2","key":"10.1016\/j.pec.2026.110342_bib24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"key":"10.1016\/j.pec.2026.110342_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2026.01.215","article-title":"Refining PARP inhibitor use in HGSOC: The role of HRD testing in clinical decision making","author":"Maradiya","year":"2026","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.pec.2026.110342_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030818","article-title":"Implementing HRD testing in routine clinical practice on patients with primary high-grade advanced ovarian cancer","volume":"15","author":"Heitz","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.pec.2026.110342_bib27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/14796694.2024.2433412","article-title":"Homologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success","volume":"21","author":"Hunt","year":"2025","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.pec.2026.110342_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6913","article-title":"Understanding communication between patients and healthcare professionals regarding comprehensive biomarker testing in precision oncology: a scoping review","volume":"13","author":"Pichler","year":"2024","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.pec.2026.110342_bib29","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3390\/curroncol32060292","article-title":"Exploring cancer patients\u2019 and caregivers\u2019 perspectives and knowledge regarding biomarker testing in Canada","volume":"32","author":"Mksyartinian","year":"2025","journal-title":"Curr Oncol"},{"key":"10.1016\/j.pec.2026.110342_bib30","unstructured":"They Know What They\u2019re Doing, but I Know What I\u2019ve Been Through\u201d: A Qualitative Study of Patients With Advanced Ovarian Cancer Describing Treatment Decision-Making Discussions and Trust in Their Providers - ProQuest [Internet]. [cited 2025 Dec 1]. Available from: https:\/\/www.proquest.com\/openview\/d3892b1a8fc0f4dc2ae2c29ca0442b3f\/1?pq-origsite=gscholar&cbl=18750&diss=y."},{"issue":"5","key":"10.1016\/j.pec.2026.110342_bib31","first-page":"2663","article-title":"I think that a brief conversation from their provider can go a very long way\u201d: patient and provider perspectives on barriers and facilitators of genetic testing after ovarian cancer","volume":"29","author":"Mallen","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.pec.2026.110342_bib32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ygyno.2025.08.009","article-title":"What you\u2019re hearing from all of us is simplify the language\u201d: patient perspectives on biomarker testing in ovarian cancer","volume":"201","author":"Smith","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.pec.2026.110342_bib33","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/curroncol31030107","article-title":"The Development and testing of a patient decision aid for individuals with homologous recombinant proficient ovarian cancer who are considering Niraparib maintenance therapy","volume":"31","author":"Hopkins","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.pec.2026.110342_bib34","doi-asserted-by":"crossref","unstructured":"Haggerty A., Barrett A., Dine J., Iadeluca L., Smith A.J., Powell K. PARP inhibitors and maintenance treatment decision-making in advanced ovarian cancer: Patient and clinician perspectives. Gynecol Oncol. 2024;The Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women\u2019s Cancer and 2024 Winter Meeting. San Diego Convention Center, San Diego United States.190:S395\u20136. Located at: rayyan-101985621. doi:10.1016\/j.ygyno.2024.07.585.","DOI":"10.1016\/j.ygyno.2024.07.585"},{"issue":"1","key":"10.1016\/j.pec.2026.110342_bib35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ygyno.2020.10.034","article-title":"Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: a qualitative study","volume":"160","author":"Poort","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.pec.2026.110342_bib36","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ygyno.2017.05.039","article-title":"A systematic review of patient values, preferences and expectations for the treatment of recurrent ovarian cancer","volume":"146","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.pec.2026.110342_bib37","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ygyno.2020.01.026","article-title":"Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment","volume":"156","author":"Havrilesky","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pec.2026.110342_bib38","article-title":"Understanding the needs and perspectives of ovarian cancer patients when considering PARP inhibitor maintenance therapy: findings from two online community events","volume":"43","author":"Monuszko","year":"2022","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.pec.2026.110342_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.pec.2024.108158","article-title":"Reinforcing the humanity in healthcare: the Glasgow Consensus Statement on effective communication in clinical encounters","volume":"122","author":"Makoul","year":"2024","journal-title":"Patient Educ Couns"}],"container-title":["Patient Education and Counseling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073839912600875X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073839912600875X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:40:47Z","timestamp":1792096847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073839912600875X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":39,"alternative-id":["S073839912600875X"],"URL":"https:\/\/doi.org\/10.1016\/j.pec.2026.110342","relation":{},"ISSN":["0738-3991"],"issn-type":[{"value":"0738-3991","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring patient and clinician perspectives for homologous recombination deficient (HRD) biomarker testing to guide precision medicine for advanced ovarian cancer treatment: A qualitative study","name":"articletitle","label":"Article Title"},{"value":"Patient Education and Counseling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pec.2026.110342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110342"}}